Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Intangibles (2017 - 2025)

Adma Biologics' Intangibles history spans 9 years, with the latest figure at $632000.0 for Q4 2025.

  • For Q4 2025, Intangibles rose 37.39% year-over-year to $632000.0; the TTM value through Dec 2025 reached $632000.0, up 37.39%, while the annual FY2025 figure was $632000.0, 37.39% up from the prior year.
  • Intangibles reached $632000.0 in Q4 2025 per ADMA's latest filing, up from $491000.0 in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $6.1 million in Q2 2021 to a low of $321000.0 in Q1 2024.
  • Average Intangibles over 5 years is $1.9 million, with a median of $923788.5 recorded in 2022.
  • Peak YoY movement for Intangibles: soared 1067.12% in 2024, then crashed 91.18% in 2025.
  • A 5-year view of Intangibles shows it stood at $1.7 million in 2021, then plummeted by 41.4% to $1.0 million in 2022, then crashed by 50.74% to $499000.0 in 2023, then decreased by 7.82% to $460000.0 in 2024, then soared by 37.39% to $632000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Intangibles are $632000.0 (Q4 2025), $491000.0 (Q3 2025), and $527000.0 (Q2 2025).